Coherus Biosciences | CHRS - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 29.06B 523M 2025-12
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Akebia Therapeutics USD 252.96M 5.38M 2025-12
ALKERMES USD 1.93B 187.5M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amarin USD 649.88M 21.55M 2025-12
Amgen USD 29.06B 1.17B 2025-12
Baxter International USD 6.87B 61M 2025-12
Biogen USD 8.97B 37.5M 2025-12
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Coherus Biosciences USD 206.71M 254.25M 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Fujifilm JPY 1.72T 120.76B 2025-12
Gilead Sciences USD 19.89B 1.05B 2025-12
Ironwood Pharmaceuticals USD 273.84M 82.09M 2025-09
Merck USD 47.56B 10.49B 2025-09
Myriad Genetics USD 332.6M 12.2M 2025-12
Pacira USD 547.97M 14.78M 2025-12
Perrigo USD 2.8B 81.8M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
PTC Therapeutics USD 2.27B 266.14M 2025-12
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Teva Pharmaceutical Industries USD 13.95B 1.21B 2025-12
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12
Xencor USD 599.82M 81.38M 2025-12
Zoetis USD 6.77B 185M 2025-12